Document Type : Original Article(s)

Authors

1 Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

2 Department of Clinical Pathology , Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

3 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

4 Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

5 Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

6 Department of Public Health and Preventive Medicine Faculty of Medicine, Airlangga University, Surabaya

7 Department of Medical Biology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Abstract

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Acute coronary syndrome is a manifestation of CVD. In Indonesia, limited studies have been conducted on genetics as a potential risk factor for acute coronary syndrome (ACS). Consequently, this study aimed to examine the effect of the methylenetetrahydrofolate reductase (MTHFR) A1298C gene polymorphism on the incidence of ACS.
METHODS: The study employed a case-control design. Outpatients from the cardiology and internal medicine clinics at the University of Airlangga (UNAIR) Hospital in Surabaya, Indonesia, constituted the study population. The case group comprised 60 patients with a history of ACS, while the control group consisted of 30 patients without a history of cardiovascular complaints. MTHFR A12980C gene polymorphism examination was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR RFLP) method at the Tropical Disease Center UNAIR Laboratory.
RESULTS: Among the ACS group, 29 (48.1%), 13 (21.7%), and 18 (30%) of the individuals had AA, AC, and CC genotype patterns, respectively. In the control group, 16 individuals had AA (53.3%), 6 AC (20%), and 8 CC (26.7%). The C allele variant was identified in 41% of the ACS group and 37% of the control group. The odds ratio (OR) for the incidence of ACS was 1.195 (95% confidence interval [CI]; 0.381-3.752), 1.241 (95% CI; 0.481-3.486), and 1.222 (95% CI; 0.381-3.752). Chi-square analysis revealed no association between MTHFR A1298C gene polymorphism and the incidence of ACS (p > 0.05).
CONCLUSIONS: MTHFR A1298C gene polymorphism did not significantly affect ACS incidence.

Highlights

The PubMed and  Google Schoolar  links for Nugraha, Jusak R.

PubMed

Google Scholar

 

Keywords

  1. Global status report on noncommunicable disease: attaining the nine communicable diseases target; a shared responsibility: World Health Organization. Geneva; 2014.
  2. Indonesia: statistical profile:World Health Organization. Geneva; 2015.
  3. Collet JP,Thiele H, Barbato E, Barthe´le´my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal 2020:1-79.
  4. Chan MY, Du X, Eccleston D, Ma C, Mohanan PP, Ogita M, et al. Acute coronary syndrome in the Asia-Pacific region. International Journal of Cardiology 2016; 202.
  5. Piepoli MF, Corra U, Dendale P, Frederix I, Prescot E, Schmid JP, et al. Challenges in secondary prevention after acute myocardial infarction: a call for action. European Journal of Preventive Cardiology 2016; 23(18): 1994-2006.
  6. Nadar SK & Sandhu K. Genes and cardiovascular disease, where do we go from here?. Sultan Qaboos University Med J 2015; 15.
  7. Kullo IJ, Ding K, Boerwinkle E, Turner ST, Mosley Jr TH, Kardia SLR, et al. Novel genomic loci influencing plasma homocysteine levels. Stroke,2006; 37: 1703-1709.
  8. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proceedings of The National Academy of Science of the United States America 2001: 14853–14858.
  9. Mallow MR. Hyperhomocysteinemia a common and easily reversible risk factor for occlusive atherosclerosis, Circulation 1990; 81(6): 2004-2006.
  10. Chambers J, Obeid O, Refsum H, Hackett D, Hooper J, Turner RM, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000; 355 (9203): 523–527.
  11. Thygesen K, Alpert JS, Jaffe AS, Chaitman, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. Circulation 2018; 138: 618-665.
  12. Zorbozan N, Atikeler GF. Evaluation of high-sensitivity cardiac troponin measurement procedure performance in serum: the vidas 3 high sensitivity cardiac troponin I. International Journal of Biochemistry 2020; 3(3): 161-165.
  13. de Oliviera KC, Bianco B, Verrischi IT, Guedes AD, Galera BB, Galera MF. Prevalence of the polymorphism MTHFR A1298C and not MTHFR C677T is related to chromosomal aneuploidy in Brazilian turner syndrome patients. Arq Bras Endocrinol Metab 2008; 52 (8).
  14. Mohammad SA, Hamid TAM, Elkarsany MM, Elsadig AE, Bashir AM, Mohammed NM. Association of methylene tetrahydrofolate reductase gene A1298C (Rs1801131) Polymorphism with Myocardial Infarction among Sudanese Patients. Haematology International Journal 2021; 5(2):1–6.
  15. Eftychiou C, Antoniades L, Makri L, Koumas L, Costeas PA, Kyriakou E,  et al.  Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: A case-control study, Hellenic Journal of Cardiology 2012; 53(3):189–194.
  16. Alizadeh S, Djafarian K, Moradi S, Shab-Bidar S. C667T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene and susceptibility to myocardial infarction: A systematic review and meta-analysis. International Journal of Cardiology 2016; 217: 99–108.
  17. Nasiri M, Roostaei A, Ehsanian Z. Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T and A1298C polymorphisms with myocardial infarction from north of Fars Province. Research in Molecular Medicine 2014; 2(3): 36–40.
  18. Zaghloul A, Lorgoveanu C, Desai D, Balakumaran K, Chen Methylenetetrahydrofolate reductase polymorphism and premature coronary artery disease. Cureus 2019; 11(6).